1. Home
  2. CYBN vs RCKT Comparison

CYBN vs RCKT Comparison

Compare CYBN & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$8.28

Market Cap

416.1M

Sector

Health Care

ML Signal

HOLD

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

HOLD

Current Price

$3.55

Market Cap

340.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYBN
RCKT
Founded
2019
1999
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.1M
340.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CYBN
RCKT
Price
$8.28
$3.55
Analyst Decision
Strong Buy
Buy
Analyst Count
4
14
Target Price
$74.50
$29.12
AVG Volume (30 Days)
916.5K
1.9M
Earning Date
02-10-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.81
$2.19
52 Week High
$10.73
$13.35

Technical Indicators

Market Signals
Indicator
CYBN
RCKT
Relative Strength Index (RSI) 68.97 55.64
Support Level $7.85 $3.36
Resistance Level $9.12 $3.64
Average True Range (ATR) 0.51 0.18
MACD 0.15 0.01
Stochastic Oscillator 68.59 80.00

Price Performance

Historical Comparison
CYBN
RCKT

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: